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I read with great interest the editorial in the September issue
2010 of the Acta Psychiatrica Scandinavica lamenting the
current conceptualization of schizophrenia and the related
psychotic disorders (1). The authors have correctly identified
problems in our formulation of the illness and pointed out that
genome-wide association studies have only identified genetic
variants with a limited amount of explanatory power. How-
ever, I wish to point out that in their review, the authors failed
to discuss the role of structural genetic variants (i.e. genetic
duplications, deletions and rearrangements) and the risk for
developing schizophrenia. These genetic lesions, while individ-
ually rare, are collectively more common than previously
recognized, and as methods to detect them improve, they will
be found even more frequently in the near future. Structural
variants can dramatically increase the risk of developing illness
with odds ratios as high as 25 reported (2). Importantly, these
genetic lesions confer risk for schizophrenia, but not specifi-
cally. Affected relatives who share the genetic variant are also
at greatly elevated risk for autism, bipolar disorder and other
psychiatric illnesses (3, 4). The consensus building from these
studies is that there are many biological pathways that can be
affected at dozens (if not hundreds) of sensitive loci and that
each can predispose an individual to psychiatric illness. How
the damage to a particular gene(s) or pathway is translated into
one clinically recognizable disorder and not another is
currently unknown, but it speaks to the presence of broadly
shared genetic risk that cuts across our established diagnostic
boundaries of mental illness. Thus, while it is true that the
clinical presentation of schizophrenia is heterogeneous and
fails in many cases to provide a reliable set of core symptoms,
the evidence suggests that this variability may be genetically
hard-wired, possibly reflecting an important biological mech-
anism underlying the disorder. If this is indeed the case, then it
may be overly optimistic and ultimately untenable to expect
that any single set of symptoms or clinical features, including
hebephrenia, will usefully serve as a stable marker of psychi-
atric illness in the absence of understanding the underlying
disease process. Without this insight, even the most careful
phenomenological description is incomplete and fails to add
value as a diagnostic or prognostic indicator.
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We are grateful to Dr. McCarthy for his encouraging
remarks and agree that it is not possible to design studies
of the biological characteristics of schizophrenia under the
present DSM rules as these identify heterogeneous samples.
It is precisely for complex genetic studies that we offer the
means to more homogeneous sampling, thereby increasing
the chances of identifying the genetic variants that he
anticipates (1). Genetic studies now call attention to factors
that confer risk of schizophrenia, but Dr McCarthy notes
that affected relatives…are at greatly elevated risk for
autism, bipolar disorder and other psychiatric illnesses,
suggesting a non-specific vulnerability, a situation analogous
to seeking the genetic risk of mental retardation. Using
hebephrenia criteria rather than DSM schizophrenia criteria
will increase the likelihood of finding the anticipated genetic
markers.
From the historic record and the failure to biologically
clearly delineate schizophrenia, we concluded that the con-
struct of schizophrenia was too broad and fatally flawed and
re-defined it as hebephrenia. We offer specific cross-sectional
and longitudinal diagnostic criteria that include a prodrome of
childhood cognitive, emotional, and neuromotor problems,
socialization difficulties, and occasional perceptual distortions.
In the second or third decade, the sufferer experiences formal
thought disorder (paraphasic speech with agrammatisms,
derailments, neologisms), delusions of passivity (controlled
by outside forces, thought insertion, and withdrawal), auditory
hallucinations, loss of emotional expression, avolition (no
interests or plans, reduced interactions, apathy), indifference to
his present situation, and cognitive deficits. Motor disturbances
emerge and chronicity ensues.
Most patients now given the schizophrenia diagnosis do not
fit this image of hebephrenia. They reflect several different
conditions.
Refining schizophrenia as hebephrenia will identify homo-
geneous samples that will improve the likelihood of significant
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biological findings in genetic and neuroscience studies. We, as
does Dr. McCarthy, look to such studies to clarify the biology
of the syndromes.
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Lithium addition to a tricyclic antidepressant
results in optimal efficacy
DOI: 10.1111/j.1600-0447.2010.01615.x
We read with interest the comprehensive article by Spijker and
Nolen (1), who discussed the Dutch algorithm for the
pharmacological treatment of depression. We agree with their
recommendation to promote the use of algorithms in daily
practice.
With regard to step 3 of the Dutch algorithm, lithium
augmentation, the authors conclude that it is the best-
documented strategy for antidepressant non-responders, but
they do no mention whether it matters to which antidepressant
lithium is added.
However, a tricyclic antidepressant (TCA) (imipramine),
with subsequent lithium addition, for patients without remis-
sion has been found more effective than a similar strategy with
novel antidepressants in two studies (2, 3). In the first
comparison (n = 100), imipramine vs. mirtazapine (2), the
two-step strategy resulted in 64% response for the imipramine–
lithium group vs. 48% for the mirtazapine–lithium group
(remission rates were not given). In the second study
(n = 138), imipramine vs. fluvoxamine (3), remission rates
were 59% for the imipramine–lithium sample vs. 41% for
patients receiving fluvoxamine–lithium.
In the STAR*D study (4), the efficacy of lithium was
disappointing, with 16% of patients achieving remission after
9 weeks of lithium addition. The low remission rate may be
explained by suboptimal dosing of lithium, but may also be
because of the fact that lithium was added to a variety of novel
antidepressants.
As it seems likely that adding lithium to an antidepressant is
performed only once in the algorithm, it is important to realize
that adding lithium to a TCA (imipramine) appears to be
superior to adding lithium to a novel antidepressant (mirtaza-
pine, fluvoxamine).
Therefore, an algorithm for the pharmacological treatment
of depression should include an advice to add lithium to a
TCA.
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We thank our colleague Tom Birkenhäger for his comment on
our article. We fully agree that the evidence for lithium
augmentation is the strongest for augmentation to a TCA. In
the update of the Dutch Multidisciplinary Guideline, 2009 (1),
the recommendation for lithium augmentation is also formu-
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